Incidensen af hypoglykæmi i gruppen, som blev behandlet med sitagliptin (4, 9%), var signifikant lavere end i glipizidgruppen (32, 0%).
The incidence of hypoglycaemia in the sitagliptin group (4.9%) was significantly lower than that in the glipizide group (32.0%).